Bolt Biotherapeutics Inc
Follow $BOLT
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $BOLT by emailVeridion Score
BETAMEDIUM CONF · 5 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is BOLT moving today?
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
BOLT overview
Related filings and maps
Congress activity in BOLT
No receipt-qualified Congressional disclosure is present for BOLT in the cached public ledger.
BOLT contract awards, year to date.
Public federal awards linked to this ticker.
BOLT lobbying filings, year to date.
Registered lobbying filings matched to Bolt Biotherapeutics Inc.